GLP1R and type 2 diabetes mellitus: Regulatory authorities recognized that GLP-1 analogues reduce the incidence of MACEs in T2DM patients, but this is only the case for GLP-1R agonists with a molecular structure based on endogenous GLP-1 (semaglutide, liraglutide, albiglutide, and dulaglutide), as they are able to reduce the relative risk of MACEs by up to 10% [43].